Axitinib Rechallenge Restores the Anticancer Effect after Nivolumab: A Case Report

The immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) combination treatment is currently the first-line treatment for metastatic renal cell carcinoma (mRCC). However, its efficacy beyond the third-line setting is expected to be relatively poor, and high-grade toxicities can develop by...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yueh-Shih, Chang, Pei-Hung, Wang, Deng-Huang, Chen, Chun-Bing, Huang, Chi-Ying F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419223/
https://www.ncbi.nlm.nih.gov/pubmed/37569525
http://dx.doi.org/10.3390/ijms241512149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419223/
https://www.ncbi.nlm.nih.gov/pubmed/37569525
http://dx.doi.org/10.3390/ijms241512149

Ejemplares similares